Nathaniel F Wu1,2, Jun Yamamoto1,3, Michael Bouvet3, Robert M Hoffman4,3. 1. AntiCancer Inc, San Diego, CA, U.S.A. 2. Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, U.S.A. 3. Department of Surgery, University of California, San Diego, CA, U.S.A. 4. AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com.
Abstract
BACKGROUND/AIM: Osteosarcoma is a rare type of malignancy that affects mostly children and adolescents. A new procedure was designed to create an improved patient-derived orthotopic xenograft (PDOX) mouse model of osteosarcoma that more closely mimics osteosarcoma in clinical settings. Previous osteosarcoma PDOX models involved implanting a tumor fragment near the femur of nude mice in a space created by separating muscle. MATERIALS AND METHODS: A hole was created in the tibia of nude mice and an osteosarcoma tumor fragment was implanted directly into the bone. RESULTS: This procedure resulted in tumor growth in the bone similar to osteosarcoma tumors found in clinical patients. CONCLUSION: The establishment ratio for this procedure is 80% making it a practical and clinically-relevant model for screening effective therapies for osteosarcoma patients. Copyright
BACKGROUND/AIM: Osteosarcoma is a rare type of malignancy that affects mostly children and adolescents. A new procedure was designed to create an improved patient-derived orthotopic xenograft (PDOX) mouse model of osteosarcoma that more closely mimics osteosarcoma in clinical settings. Previous osteosarcoma PDOX models involved implanting a tumor fragment near the femur of nude mice in a space created by separating muscle. MATERIALS AND METHODS: A hole was created in the tibia of nude mice and an osteosarcoma tumor fragment was implanted directly into the bone. RESULTS: This procedure resulted in tumor growth in the bone similar to osteosarcoma tumors found in clinical patients. CONCLUSION: The establishment ratio for this procedure is 80% making it a practical and clinically-relevant model for screening effective therapies for osteosarcomapatients. Copyright
Authors: Jonathan Gill; Wendong Zhang; Zhongting Zhang; Michael Roth; Douglas J Harrison; Sudie Rowshan; Stephen Erickson; Gregory Gatto; Raushan Kurmasheva; Peter Houghton; Beverly Teicher; Malcolm A Smith; E Anders Kolb; Richard Gorlick Journal: Pediatr Blood Cancer Date: 2020-07-24 Impact factor: 3.167
Authors: Branden A Smeester; Nicholas J Slipek; Emily J Pomeroy; Kanut Laoharawee; Sara H Osum; Alex T Larsson; Kyle B Williams; Natalie Stratton; Kenta Yamamoto; Joseph J Peterson; Susan K Rathe; Lauren J Mills; Wendy A Hudson; Margaret R Crosby; Minjing Wang; Eric P Rahrmann; Branden S Moriarity; David A Largaespada Journal: Bone Date: 2020-04-03 Impact factor: 4.626
Authors: Aruna Marchetto; Shunya Ohmura; Martin F Orth; Maximilian M L Knott; Maria V Colombo; Chiara Arrigoni; Victor Bardinet; David Saucier; Fabienne S Wehweck; Jing Li; Stefanie Stein; Julia S Gerke; Michaela C Baldauf; Julian Musa; Marlene Dallmayer; Laura Romero-Pérez; Tilman L B Hölting; James F Amatruda; Andrea Cossarizza; Anton G Henssen; Thomas Kirchner; Matteo Moretti; Florencia Cidre-Aranaz; Giuseppina Sannino; Thomas G P Grünewald Journal: Nat Commun Date: 2020-05-15 Impact factor: 14.919